| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.9 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.011 | 0.9 |